Ares Allergy Holdings News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

31.05.19	Stallergenes Greer Will Be at 2019 EAACI Congress and Present the Results of Its Phase III House Dust Mites Tablet Trial (Businesswire)
05.04.19	Recommended Cash Acquisition of Stallergenes Greer plc ("Stallergenes Greer") by Ares Life Sciences I S.à r.l. ("Waypoint") (Businesswire)
20.11.18	Stallergenes Greer Announces That the Phase III Trial for Its Sublingual Allergy Immunotherapy Tablet STAGR320 to Treat House Dust Mite-Induced Allergic Rhinitis Achieved Its Primary Endpoint (Businesswire)
14.11.18	Stallergenes Greer Announces U.S. FDA Approval of Pediatric Indication Extension for Oralair® Sublingual Immunotherapy Tablet for the Treatment of Grass Pollen Allergy (Businesswire)
29.08.18	Stallergenes Greer Delivers Double Digit Growth and Solid Business Performance in the First Half of 2018; Announces Senior Leadership Succession Plan (Businesswire)
07.06.18	Stallergenes Greer Provides Business Update and Refines Its 2018 Financial Outlook (Businesswire)
23.04.18	Notification to Stallergenes Greer Shareholders of Annual General Meeting on 7 June 2018 (Businesswire)
15.03.18	Stallergenes Greer to Report Full Year Financial Results on 22 March 2018 (Businesswire)
16.02.18	Stallergenes Greer Announces Approval in Japan of Pediatric Use for ACTAIR®, Sublingual Immunotherapy Tablet for the Treatment of House Dust Mite Allergy (Businesswire)
25.01.18	Stallergenes Greer Comments on Share Price Movement (Businesswire)
25.10.17	Stallergenes Greer’s 2017 Innovation Day (Businesswire)
25.10.17	Stallergenes Greer Invests in Adeo Health Science, a Research-Driven Food Company with a Novel Approach in Food Allergy (Businesswire)
02.10.17	Stallergenes Greer Acquires Canadian Medic Savoure, Strengthening Presence in North America (Businesswire)
26.09.17	Stallergenes Greer Advances Its House Dust Mite Allergy Pipeline with Acceptance of Regulatory Submission and New Market Approval (Businesswire)
31.08.17	Stallergenes Greer Reports Strong First Half 2017 Results and Narrows 2017 Financial Guidance (Businesswire)
27.07.17	Stallergenes Greer Announces Completion of Enrollment in Largest Phase III Study to Treat House Dust Mites Allergy (Businesswire)
19.06.17	Stallergenes Greer plc: First Real-World Evidence Shows Long Term Benefits of Sublingual Immunotherapy to Control Allergic Rhinitis and Potentially Prevent Allergic Asthma (Businesswire)
01.12.16	Stallergenes Greer Secures €50M Revolving Credit Facility (Businesswire)
16.11.16	Stallergenes Greer’s "Meet the Managers” Event Showcases Progress towards Regaining Global Leadership in Its Field (Businesswire)
14.11.16	Stallergenes Greer Announces Collaboration with the Sean N. Parker Center for Allergy and Asthma Research at Stanford University (Businesswire)
07.10.16	Stallergenes Greer plc: Director/PDMR Shareholding (Businesswire)
09.06.16	Stallergenes Greer Announces Results of 2016 Annual General Meeting (Businesswire)
27.05.16	Update on Stallergenes Greer Manufacturing and Distribution Activities (Businesswire)
04.05.16	Stallergenes Greer plc : Notification to Shareholders of Annual General Meeting on 9 June 2016 (Businesswire)
29.04.16	Stallergenes Greer Announces the Publication of Its 2015 Annual Report (Businesswire)
27.04.16	Stallergenes Greer Announces Its 2015 Full Year Results (Businesswire)
27.04.16	Stallergenes Greer Reports Positive Phase II Japanese Cedar Immunotherapy Tablets Results (Businesswire)
11.04.16	Stallergenes Greer PLC: Daniel Smith Appointed Global Head of Information Technology (Businesswire)
05.04.16	Stallergenes Greer Announces the Approval of ACTAIR® in Australia (Businesswire)
11.03.16	Stallergenes Greer PLC: Notifice to Shareholders of Adoption of Financial Reporting Standard ("FRS”) 102 – ‘Reduced Disclosure Framework’ for Parent Entity (Businesswire)
10.03.16	Stallergenes Greer Authorized to Resume Named Patient Products Manufacturing at Its Antony, France Plant (Businesswire)
22.02.16	Stallergenes Greer Announces Its 2016 Financial Calendar (Businesswire)
10.02.16	Stallergenes Greer PLC: Michele Antonelli Appointed President of Stallergenes SAS and Executive Vice President, Head of Europe & Rest of World (Businesswire)
01.02.16	Stallergenes Greer Announces Resumption of Manufacturing at Its Antony, France Plant (Businesswire)
01.02.16	Stallergenes Greer PLC: Tibor Nemes zum Global Head of Technical Operations berufen (Businesswire)
01.02.16	Stallergenes Greer PLC: Tibor Nemes Appointed Global Head of Technical Operations (Businesswire)
07.12.15	Stallergenes Greer PLC: Recall of Allergy Immunotherapy Products (Businesswire)
02.12.15	Stallergenes Greer Announces a Temporary Suspension of Manufacturing at Its Stallergenes Antony Plant (Businesswire)
19.11.15	Stallergenes Greer Announces the Launch of Actair® in Japan (Businesswire)
10.11.15	Stallergenes Greer Appoints Michele Antonelli as Executive Vice President, Head of International Operations (Businesswire)
06.11.15	Stallergenes Greer PLC : Introducing a New Global Allergy Company (Businesswire)
27.10.15	Ares Allergy Holdings plc Becomes Stallergenes Greer plc (Businesswire)
23.10.15	Ares Allergy Holdings plc Updates on the Development of Its House Dust Mite Sublingual Immunotherapy Tablet in Allergic Asthma (Businesswire)
14.10.15	Ares Allergy Holdings plc to Hold Business Update on 5 November 2015 and Announces Financial Reporting Schedule (Businesswire)
30.09.15	Ares Allergy Holdings plc Publishes Half-Year 2015 Report and Financial Statements (Businesswire)
21.09.15	Ares Allergy Holdings Plc: Notice of Extraordinary General Meeting on 27 October 2015 (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	50.28	1.62 %	K V
UBS Group	28.48	1.42 %	K V
CieFinRichemont	122.70	1.24 %	K V
Lonza Grp	526.40	1.15 %	K V
Part Grp Hldg	1’280.00	1.11 %	K V
Sonova Hldg	300.80	-0.07 %	K V
Sika	228.10	-0.09 %	K V
Novartis	93.27	-0.12 %	K V
Nestle	76.48	-0.21 %	K V
Swisscom	508.50	-0.29 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Ares Allergy Holdings PLC

Aktien Top/Flop

Meistgelesene Nachrichten